

ORAL PRESENTATION

Open Access

Post-radioiodine management of patients with Graves' disease

K Collins*, P Perros, J Horsefield

From International Conference for Healthcare and Medical Students 2011
Dublin, Ireland. 4-5 November 2011

Introduction

Radioiodine is a safe and effective treatment for Graves' disease. Iatrogenic hypothyroidism is very common after treatment, but its onset is unpredictable. Even a short episode of hypothyroidism can result in significant morbidity and ideally should be avoided. In Newcastle a standard dose of radioiodine (400MBq) is used, but for historical reasons two different protocols are used after radioiodine: Regimen A: regular clinical and biochemical monitoring and initiation of levothyroxine when serum thyroid hormones have normalized, and Regimen B: block and replace with Carbimazole and levothyroxine starting 2 weeks post-radioiodine and continuing for 6 months, then withdrawing Carbimazole, but continuing with levothyroxine long-term.

Methods

The objective was to compare the two protocols for incidence of biochemical and clinical hypothyroidism during a 12 month post-radioiodine follow-up period and effects on weight gain and development or progression of orbitopathy. Patients with Graves' disease who were treated between January 2008-December 2009 were included. The medical records were reviewed and data were collected and analyzed.

Results

One hundred and twenty two patients were studied, 78 treated with Regimen A and 43 with Regimen B. Euthyroidism at 8 weeks, 6 months and 12 months post-radioiodine was achieved in 50%, 64% and 73% of patients with Regimen A and 65.1%, 71% and 65% in patients with regimen B respectively. Clinical hypothyroidism during follow-up was commoner in Regimen A than B (52.6% vs 16.3% respectively, $p < 0.05$). Weight gain was reported more frequently

in Regimen A than B (43.6% vs 20.9%, $p < 0.05$). The incidence of new Graves' orbitopathy developing after radioiodine was higher in Regimen A than B (11.1% vs 5.3%).

Conclusions

A 6 month course of block and replace followed by levothyroxine after a standard 400MBq dose of radioiodine is associated with better clinical outcomes than a watchful approach and initiation of levothyroxine based on biochemical and clinical indicators.

Published: 9 July 2012

doi:10.1186/1753-6561-6-S4-O37

Cite this article as: Collins et al.: Post-radioiodine management of patients with Graves' disease. *BMC Proceedings* 2012 **6**(Suppl 4):O37.

Submit your next manuscript to BioMed Central
and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

BioMed Central

Departments of Endocrinology and Medical Physics, Royal Victoria Infirmary,
Newcastle upon Tyne, UK